An Open-Label Extension Study to Assess the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder. [EXTENSION OF 700034966]

Trial Profile

An Open-Label Extension Study to Assess the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder. [EXTENSION OF 700034966]

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2013

At a glance

  • Drugs Buspirone/melatonin (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top